ClinicalTrials.gg
CompletedNCT00919815Updated Mar 24, 2015

Ciclosporin in the Management of New Type 1 Reactions in Leprosy

A Phase 2/3 interventional study of Ciclosporin and Prednisolone in Leprosy, sponsored by London School of Hygiene and Tropical Medicine. Completed at 1 site in Ethiopia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-03-24.

Sponsored by London School of Hygiene and Tropical Medicine · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Study 1A: Ciclosporin in the management of new Type 1 Reactions in Leprosy

Objective: A randomised double blind controlled trial comparing Ciclosporin and Prednisolone,to determine whether treatment with Ciclosporin gives the same outcome in the treatment of new Type 1 Reactions as Prednisolone.

Read the detailed description

We tested our hypothesis that ciclosporin would be as effective as prednisolone in the treatment of patients with leprosy reactions and nerve function impairment and that patients treated with ciclosporin would have fewer side effects than patients treated with prednisolone. A randomised controlled trial comparing ciclosporin and prednisolone in the treatment of acute leprosy T1R was conducted.

02

Conditions studied

  • Leprosy

Browse trials for

Keywords

  • Leprosy
  • Type 1 Reactions
  • Prednisolone
  • Ciclosporin
03

In context

Leprosy

52 studies on the registry are indexed under Leprosy; 13 are open to participants now.

This study's enrollment of 73 is close to the median of 70 across 41 interventional studies indexed under Leprosy.

Browse Leprosy studies →

Lead sponsor

London School of Hygiene and Tropical Medicine is the lead sponsor of 298 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with clinical evidence of T1R with new nerve function impairment (NFI).
  • Aged 18-65
  • Weigh more than 30Kg

Exclusion criteria

Exclusion Criteria:

  • Unwillingness to give
  • Patients with severe active infections such as tuberculosis
  • Pregnant or breastfeeding women (see Appendix II)
  • Those with renal failure, abnormal renal function, hypertensive
  • Patients taking thalidomide currently or within the last 3 months
  • Patients not willing to return for follow-up
  • Women of reproductive age not willing to use for the duration of the study ( see Appendix II)
  • positive patients
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    ciclosporin arm

    ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)

    Drug: Ciclosporin

  • Active comparator
    prednisolone

    standard course of prednisolone given in a reducing regimen over 24 weeks

    Drug: Prednisolone

Interventions

  • Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)

    Also known as: Cyclosporine, Cyclosporine A

  • prednisolone 40mg daily then reducing regimen over 24 weeks

    Also known as: corticosteroids

06

What researchers measure

Primary outcomes

  1. improvement in nerve function and Clinical Severity Score

    Time frame: at week 4, 20, 28

Secondary outcomes

  1. Incidence of adverse events

    Time frame: up to 36 weeks

  2. Number of T1R recurrence episodes per patient in each treatment arm

    Time frame: up to 36 weeks

  3. Severity of T1R recurrence for patients in each treatment arm

    Time frame: up to 36 weeks

  4. extra prednisolone needed to control reaction

    Time frame: up to 36 weeks

  5. 6. Difference in score in Quality of Life assessment between start and end of treatment for patients in each treatment arm

    Time frame: 36 weeks

  6. Mean time to recurrence of T1R for patients in each treatment arm

    Time frame: up to 36 weeks

07

Study locations

1 site
  • Alert Hospital
    Addis Abeba, Ethiopia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00919815
Collaborators
Homes and Hospitals of St Giles, Alert Hospital, Ethiopia, Armauer Hansen Research Institute, Ethiopia
Responsible party
Saba Lambert (Clinical Research Fellow, London School of Hygiene and Tropical Medicine) — Principal investigator
First posted
Jun 12, 2009
Start date
Aug 2010
Primary completion
Dec 2012
Completion
Jul 2013
Last update
Mar 24, 2015

Study contacts

Diana Lockwood, MBChB
principal investigator · London School of Hygiene and Tropical Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion